Genta Initiates Randomized Trial of Tesetaxel as First-Line Therapy for Women With Recurrent Breast Cancer

-- "All Oral Chemotherapy" Study Compares Two Different Schedules of Tesetaxel With Capecitabine BERKELEY HEIGHTS, N.J., May 31, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (GNTA) announced today that the first patient has been accrued to a new randomized trial of tesetaxel as initial chemotherapy for women with advanced or recurrent breast cancer. The trial -- a randomized, three-arm, Phase 2b study that is expected to accrue approximately 220 patients -- will be conducted at approximately 15 sites...continued GNTA  docetaxel paclitaxel oncology

URL: http://www.investorpoint.com/news/OTCBULLB/51690598/